trending Market Intelligence /marketintelligence/en/news-insights/trending/XrG7sreKViIB2h9wkZmoSw2 content esgSubNav
In This List

Stemline Therapeutics plans common stock offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Stemline Therapeutics plans common stock offering

Stemline Therapeutics Inc. plans to sell 6,600,000 common shares through an underwritten public offering.

The New York-based cancer drug developer expects to grant underwriters a 30-day option to buy up to 990,000 additional common shares.

Net proceeds will be used on commercial activities for Elzonris, Stemline Therapeutics' treatment for blastic plasmacytoid dendritic cell neoplasm, a rare blood disease. Funds will also go toward clinical trials, including those for additional indications of Elzonris, research and development activities, potential acquisitions and in-licensing, as well as other general corporate purposes.

J.P. Morgan Securities LLC is acting as book-running manager for the offering.